-
Siemens Medical's Corindus Interventional Surgery Robot successfully completes China's first operation in Boao
Time of Update: 2021-07-18
After the operation, Siemens Healthcare joined hands with the team of Academician Ge Junbo, Hainan Boao Super Hospital, Boao Lecheng International Medical Tourism Pilot Zone Administration, and Huayi Xincheng Doctor Group to celebrate the success of the first operation and held the Corindus Turing™ interventional surgical robot.
-
BioXcel's dementia drug BXCL501 receives FDA breakthrough therapy certification
Time of Update: 2021-07-18
A few days ago, BioXcel Therapeutics announced that its research and proprietary oral soluble dexmedetomidine sublingual film preparation BXCL501 has been approved by the FDA as a breakthrough therapy for acute agitation symptoms in patients with Alzheimer’s disease.
-
Hengrui Medicine: The clinical trial of SHR-1707 injection was approved by the State Food and Drug Administration
Time of Update: 2021-07-18
At present, similar products of many companies are in the clinical research and development stage, and the indication is Alzheimer's disease .
Up to now, the accumulated research and development expenses of SHR-1707 related projects are approximately RMB 40.
-
AbbVie plans to sell women's drug portfolio assets for $5 billion
Time of Update: 2021-07-17
According to a recent report by French Reuters, AbbVie is currently planning to sell some of the female drug assets acquired by the acquisition of Allergan, which may include the contraceptive Lo Loestrin Fe .
-
BioVaxys and WuXi Biologics Sign Biological Production Agreement
Time of Update: 2021-07-17
According to the terms of the agreement, WuXi Biologics will synthesize high-yield fully characterized GLP-grade SARS-CoV-2 virus S protein for use in the preclinical safety study of BioVaxys' COVID-T™ diagnostic method .
-
Cardano signed a definitive agreement to sell its Cordis business to Hellman&Friedman
Time of Update: 2021-07-17
" Hunter Philbrick, a partner of H&F, said: “Cordis, as one of the market’s leading manufacturers of cardiovascular medical devices, is known for its high-quality products, extremely high doctor satisfaction, and excellent patient diagnosis and treatment results.
-
Chuangsheng Group's continuous perfusion platform achieves a daily volumetric productivity of >6g/L
Time of Update: 2021-07-17
Chuangsheng Group, an international biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical R&D, clinical and process development, and production, recently announced that its continuous perfusion cell culture platform has achieved a major breakthrough.
-
Betta Pharmaceuticals' MCLA-129 injection was approved to carry out clinical trials of advanced solid tumors
Time of Update: 2021-07-17
In January 2021, Betta Pharmaceuticals submitted a drug clinical trial application for MCLA-129 injection for the aforementioned indications to the State Food and Drug Administration and was accepted .
-
The State Food and Drug Administration issued a notice on the voluntary recall of medical devices by 4 product companies including Sofradim
Time of Update: 2021-07-17
Among them, the reason for Sofradim Products’ recall was due to the problem of packaging errors involving specific models and batches of products; the reason for the recall of Kevin Inman Co.
-
The reason why BMS suspends the pharmaceutical business of a Chinese subsidiary is actually...
Time of Update: 2021-07-17
On March 15, the Jiangsu Provincial Drug Administration issued an announcement stating that in accordance with the "Administrative Licensing Law", "Drug Administration Law", "Drug Distribution License Management Measures" and other relevant regulations, Bristol-Myers Squibb (China) Pharmaceutical Co.
-
Ping An of China and Zhongshan Hospital sign a strategic cooperation agreement
Time of Update: 2021-07-17
Chen Xinying, Co-CEO of Ping An of China, and Fan Jia, academician of the Chinese Academy of Sciences and President of Zhongshan Hospital, attended the signing ceremony.
-
WuXi Hyde's Irish vaccine production base completes the main building construction as scheduled under the new crown epidemic
Time of Update: 2021-07-17
WuXi Hyde, the global vaccine industry's leading integrated capability and technology empowerment platform, today announced that its vaccine production base in the Irish campus is still completing the main building construction on schedule despite the severe situation of the local new crown epidemic, and is expected to be put into operation in 2022 Operations .
-
2021EBMT Lu Daopei Medical Team Director Zhao Yanli reports the latest research results
Time of Update: 2021-07-17
Comparison of refractory/relapsed and high-risk B-ALL) First author: Zhao Yanli, abstract number: OS3-7 Background: Antithymocyte globulin (ATG) plays an important role in the prevention of graft-versus-host disease (GVHD) after haploid stem cell transplantation (haplo-SCT) .
-
Luye Pharma and Italfarmaco Group reached an agreement for the commercialization of a new Alzheimer's disease drug Lis' Mindoday transdermal patch in four European countries
Time of Update: 2021-07-17
Luye Pharmaceuticals (Switzerland), a subsidiary of Luye Pharmaceutical Group, has reached an agreement with Italfarmaco Group (Italfarmaco) to grant the latter the exclusive right to commercialize Liss’ Mindoday transdermal patches in four European countries .
-
Pfizer stopped the production of biosimilars in China, and the former "golden track" no longer exists?
Time of Update: 2021-07-17
Constantly missing the domestic market According to external news, a Pfizer spokesperson said that the biopharmaceutical production base sold this time originally planned to produce three biosimilar drugs in China: Roche Bevacizumab (Avastin) and Trastuzumab (Herceptin).
-
Yuyue Medical: Deepen Collaborative Innovation and Build Smart Medical Consortium
Time of Update: 2021-07-17
Yuyue Medical, a leading medical device company in China, has joined hands with many Class-A hospitals across the country to establish a smart medical platform integrating scientific research, products, and data .
-
Italfarmaco obtained the exclusive commercial rights of Luye Pharma's Lismindo Day transdermal patch
Time of Update: 2021-07-17
According to the agreement, Italfarmaco has the exclusive right to commercialize Liss’ Mindoday patch in Germany, Italy, Portugal and Greece (the "region") .
-
Cancellation of 1 subsidiary and suspension of sales of 12 medicines
Time of Update: 2021-07-17
BMS Wuxi subsidiary once announced that it is mainly engaged in biological products, including distribution and refrigeration According to an enterprise search, the American pharmaceutical company Bristol-Myers Squibb (BSM) has established a subsidiary Bristol-Myers Squibb (China) Investment Co.
-
Hengrui Medicine Fluzoparib Capsules and Abiraterone Acetate Tablets Clinical Trials Approved
Time of Update: 2021-07-17
Domestic Zai Lab's Nirapali Tosylate Capsules (trade name Zile) was approved for marketing in China in December 2019 for platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer Maintenance treatment for adult patients after platinum-containing chemotherapy has achieved complete or partial remission .
-
WuXi Biologics Announces Acquisition of Pfizer's China Biologics Liquid and Preparation Production Base
Time of Update: 2021-07-17
WuXi Biologics, the world’s leading open biopharmaceutical technology platform company, today announced that it has reached an acquisition agreement with Pfizer China.
WuXi Biologics will acquire Pfizer China’s advanced biopharmaceutical production base in Hangzhou.
